ATE498010T1 - Natürliche igm-antikörper und inhibitoren davon - Google Patents

Natürliche igm-antikörper und inhibitoren davon

Info

Publication number
ATE498010T1
ATE498010T1 AT05723931T AT05723931T ATE498010T1 AT E498010 T1 ATE498010 T1 AT E498010T1 AT 05723931 T AT05723931 T AT 05723931T AT 05723931 T AT05723931 T AT 05723931T AT E498010 T1 ATE498010 T1 AT E498010T1
Authority
AT
Austria
Prior art keywords
inhibitors
natural igm
igm antibodies
natural
disorders
Prior art date
Application number
AT05723931T
Other languages
English (en)
Inventor
Michael Carroll
Francis D Moore Jr
Herbert Hechtman
Original Assignee
Immune Disease Inst Inc
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Disease Inst Inc, Harvard College filed Critical Immune Disease Inst Inc
Application granted granted Critical
Publication of ATE498010T1 publication Critical patent/ATE498010T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05723931T 2004-03-01 2005-03-01 Natürliche igm-antikörper und inhibitoren davon ATE498010T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54912304P 2004-03-01 2004-03-01
US58864804P 2004-07-16 2004-07-16
PCT/US2005/006276 WO2005085288A2 (en) 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof

Publications (1)

Publication Number Publication Date
ATE498010T1 true ATE498010T1 (de) 2011-02-15

Family

ID=34922704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723931T ATE498010T1 (de) 2004-03-01 2005-03-01 Natürliche igm-antikörper und inhibitoren davon

Country Status (9)

Country Link
US (5) US7442783B2 (de)
EP (2) EP1725659B1 (de)
JP (3) JP5557982B2 (de)
AT (1) ATE498010T1 (de)
AU (1) AU2005219839B9 (de)
CA (1) CA2560066A1 (de)
DE (1) DE602005026260D1 (de)
IL (1) IL177825A (de)
WO (1) WO2005085288A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085288A2 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research Natural igm antibodies and inhibitors thereof
US20100136684A1 (en) * 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
AU2010328359B2 (en) * 2009-12-07 2015-02-05 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
CN103221062A (zh) * 2010-06-03 2013-07-24 阿布拉西斯生物科学有限责任公司 外周血sparc 结合抗体及其用途
WO2014055392A2 (en) * 2012-10-01 2014-04-10 Decimmune Therapeutics, Inc. Method of protecting cardiac function
CA2905940A1 (en) 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Humanized, anti-n2 antibodies
JP6551825B2 (ja) * 2014-02-10 2019-07-31 公立大学法人首都大学東京 クロマチン構造制御剤

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0411060A4 (en) 1988-09-06 1991-04-03 Asarco Incorporated Method and burner for melting copper
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP0502060A4 (en) 1989-11-13 1993-05-05 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
AU7163091A (en) * 1989-12-12 1991-07-18 Biomedical Research Institute Novel malarial sporozoite peptide antigens
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP0562025B1 (de) 1990-12-06 2001-02-07 Affymetrix, Inc. (a Delaware Corporation) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993009668A1 (en) 1991-11-22 1993-05-27 Affymax Technology N.V. Combinatorial strategies for polymer synthesis
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
PT665897E (pt) 1992-10-01 2003-11-28 Trustees Of Columbia U In The Bibliotecas quimicas combinatorias complexas codificadas com etiquetas
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1135535A2 (de) * 1998-12-03 2001-09-26 Phagetech Inc. Entwicklung von antimikrobiellen mittel auf der basis des bakteriophagen-genoms
WO2000042210A2 (en) 1999-01-15 2000-07-20 International Paper Company Microsatellite dna markers and uses thereof
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
AU5625500A (en) * 1999-06-18 2001-01-09 Emory University Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001263006A1 (en) * 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001275378A1 (en) * 2000-06-08 2001-12-17 The Center For Blood Research, Inc. Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury
CA2424379C (en) * 2000-10-10 2013-10-01 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US7319139B2 (en) * 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
US20040131607A1 (en) 2001-06-08 2004-07-08 Carroll Michael C. Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
AU2002364105A1 (en) * 2001-12-21 2003-07-15 Diadexus, Inc. Compositions and methods relating to endometrial specific genes and proteins
AU2002357382A1 (en) * 2001-12-21 2003-07-30 Diadexus, Inc. Compositions and methods relating to endometrial specific genes and proteins
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005085288A2 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research Natural igm antibodies and inhibitors thereof
US20100136684A1 (en) 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
DE602005026260D1 (de) 2011-03-24
AU2005219839A1 (en) 2005-09-15
IL177825A (en) 2013-02-28
AU2005219839B2 (en) 2011-11-24
EP2290077A3 (de) 2011-05-18
US7442783B2 (en) 2008-10-28
US9914751B2 (en) 2018-03-13
US20170342109A1 (en) 2017-11-30
WO2005085288A2 (en) 2005-09-15
JP2008504807A (ja) 2008-02-21
US20050276811A1 (en) 2005-12-15
CA2560066A1 (en) 2005-09-15
EP1725659A2 (de) 2006-11-29
US9657060B2 (en) 2017-05-23
WO2005085288A3 (en) 2006-08-03
JP2014155497A (ja) 2014-08-28
JP2011139704A (ja) 2011-07-21
IL177825A0 (en) 2006-12-31
US20090176966A1 (en) 2009-07-09
EP2290077B1 (de) 2016-01-27
US20140127214A1 (en) 2014-05-08
EP2290077A2 (de) 2011-03-02
JP5557982B2 (ja) 2014-07-23
HK1154904A1 (en) 2012-05-04
EP1725659B1 (de) 2011-02-09
AU2005219839B9 (en) 2011-12-22
JP5618852B2 (ja) 2014-11-05
US20160280740A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY2021009I2 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι χρησης αυτων στην αντιμετωπιση φλεγμονωδων νοσων
IS8451A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
KR101528970B9 (ko) 항체의 농축 방법 및 이의 치료용 생성물
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
ATE423571T1 (de) Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
CY1112912T1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
AR054233A1 (es) Composiciones de anticuerpos igg2
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
CY1110188T1 (el) Αντισωματα κατα συζυγων φωσφορυλχολινης
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
ATE461219T1 (de) Therapeutische humanisierte antikörper gegen cd45-isoformen
ATE494890T1 (de) Alpha-aminoamid-derivate zur behandlung von suchtstörungen
EA200701306A1 (ru) Лиофилизация виросом
DE602005023452D1 (de) Mit calcitriol und clobetasolpropionat zur behandlung von schuppenflechte
ATE549416T1 (de) Verfahren und zusammensetzungen zum nachweis von autoimmunkrankheiten
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties